-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JL1GxK2kd0BHSimt3+edck+LKmyywZGs6/VxJNoLbMEf99MSRQbwz3NJGSFhohUx zILx9j0sQjk8n5xvgTYcwA== 0000914260-01-500017.txt : 20010914 0000914260-01-500017.hdr.sgml : 20010914 ACCESSION NUMBER: 0000914260-01-500017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010912 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20010913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INNOVATIVE CLINICAL SOLUTIONS LTD CENTRAL INDEX KEY: 0001002022 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 650617076 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27568 FILM NUMBER: 1736342 BUSINESS ADDRESS: STREET 1: 10 DORRANCE ST STREET 2: STE 400 CITY: PROVIDENCE STATE: RI ZIP: 02903 BUSINESS PHONE: 4018316755 MAIL ADDRESS: STREET 1: 10 DORRANCE STREET STREET 2: SUITE 400 CITY: PROVIDENCE STATE: RI ZIP: 02903 FORMER COMPANY: FORMER CONFORMED NAME: CONTINUUM CARE CORP DATE OF NAME CHANGE: 19951010 FORMER COMPANY: FORMER CONFORMED NAME: PHYMATRIX CORP DATE OF NAME CHANGE: 19951229 8-K 1 form8k.htm FORM 8-K form 8-k SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 --------------------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2001 (August 31, 2001) - ------------------------------------------------------------------------------------------------------------------------------------------------ INNOVATIVE CLINICAL SOLUTIONS, LTD. - ------------------------------------------------------------------------------------------------------------------------------------------------ (Exact name of registrant as specified in its charter) Delaware - ----------------------------------------------------------------------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 0-27568 65-0617076 - ------------------------------------------------------------------------------------------------------------------------------------------------ (Commission File Number) (IRS Employer Identification Number) 10 Dorrance Street, Suite 400, Providence, RI 02903 - ------------------------------------------------------------------------------------------------------------------------------------------------ (Address of principal executive offices) (401) 831-6755 - ------------------------------------------------------------------------------------------------------------------------------------------------ (Registrant's telephone number, including area code) N/A - ------------------------------------------------------------------------------------------------------------------------------------------------ (Former name or former address, if changed since last report) Item 5: Other Events. - ------ ------------ Resignation of Adrian Otte - -------------------------- The Registrant announced that its Chief Operating Officer - Clinical Studies, Dr. Adrian Otte, has tendered his resignation and the Registrant has accepted his resignation. Dr. Otte resigned to pursue an opportunity as a senior manager for major pharmaceutical company. Dr. Otte's resignation will be effective September 14, 2001. Gary S. Gillheeney, the Registrant's Chief Financial Officer will serve as interim Chief Operating Officer - Clinical Studies until a suitable replacement for Dr. Otte can be retained. Sale of Oncology - ---------------- On August 31, 2001, the Registrant sold certain of its assets, specifically its oncology clinical studies (OCS) network of 23 sites across the country. The Registrant received $2.5 million in cash for the OCS network and plans to use that cash to focus on its core competencies. Item 7. Financial Statements and Exhibits. (a) Financial statements of business acquired. Not Applicable (b) Pro forma financial information Not Applicable (c) Exhibits None. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INNOVATIVE CLINICAL SOLUTIONS, LTD By: /s/ Michael T. Heffernan ----------------------------------- Michael T. Heffernan Chief Executive Officer Date: August 11, 2001 -----END PRIVACY-ENHANCED MESSAGE-----